Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
Condition(s):Multiple SclerosisLast Updated:November 8, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Multiple SclerosisLast Updated:November 8, 2022Completed
Condition(s):Friedreich AtaxiaLast Updated:February 29, 2024Completed
Condition(s):SunscreenLast Updated:October 25, 2023Completed
Condition(s):Parkinson Disease; ParkinsonLast Updated:September 22, 2022Recruiting
Condition(s):Metastatic Colorectal CancerLast Updated:January 26, 2023Completed
Condition(s):Weight Loss; Time Restricted Feeding; Bone LossLast Updated:October 19, 2023Recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:September 15, 2022Completed
Condition(s):Prader-Willi Syndrome; ObesityLast Updated:February 12, 2024Completed
Condition(s):Infertility of Uterine OriginLast Updated:October 27, 2023Recruiting
Condition(s):Problem Behavior; Aggression; Self-InjuryLast Updated:December 21, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.